PDCD1LG2 and cancer: Therefore, it is important to consider the spatial and temporal heterogeneity of the tumor immune microenvironment and the discordance between PD-L1 and PD-L2 expression in tumors when cancer patients are treated with PD-1 or PD-L1 inhibitors.